What are the current guidelines for diagnosing and managing acanthosis nigricans, including evaluation for insulin resistance, obesity, malignancy, and appropriate treatment options?

Acanthosis Nigricans: Clinical Guidelines for Diagnosis and Management

Immediate Diagnostic Evaluation

When acanthosis nigricans is identified, immediately screen for insulin resistance and diabetes with fasting plasma glucose followed by a 2-hour oral glucose tolerance test (75-gram glucose load), as this cutaneous finding is a strong marker of metabolic dysfunction. 1, 2, 3

Essential Laboratory Work-Up

• Glucose metabolism assessment: Perform fasting plasma glucose followed by 2-hour OGTT (75g load) as the ACOG-endorsed standard for detecting diabetes and impaired glucose tolerance 1, 2, 3
• Hemoglobin A1C: Measure to identify prediabetes (values 5.7-6.4%) 3
• Fasting insulin levels: Assess directly for insulin resistance (normal <15 mU/L; borderline 15-20 mU/L; high >20 mU/L) 4, 3
• Lipid panel: Obtain fasting lipids including total cholesterol, LDL, HDL, and triglycerides, as AN signals dyslipidemia with elevated triglycerides, increased LDL, and reduced HDL 1, 3
• Thyroid function: Measure TSH to exclude thyroid disease 1, 2, 3

Endocrine and Malignancy Screening

• In women: Assess serum prolactin and total/free testosterone to identify PCOS-related hyperandrogenism, as AN is strongly linked to polycystic ovary syndrome with chronic anovulation and hyperinsulinemia 1, 2, 3
• Physical examination findings: Document presence of acne, hirsutism, clitoromegaly, menstrual irregularities, or ovarian enlargement on pelvic exam 2, 3
• Cushing's syndrome: If clinical stigmata are present (moon facies, centripetal obesity, hypertension, striae, buffalo hump), initiate formal biochemical testing with 24-hour urinary free cortisol, late-night salivary cortisol, or low-dose dexamethasone suppression test 1, 3
• Malignancy investigation: For non-obese patients, rapid AN onset, extensive involvement, or "tripe palms" (palmar involvement), pursue age-appropriate cancer screening with emphasis on gastric adenocarcinoma through imaging and upper gastrointestinal endoscopy 1, 3

Pediatric-Specific Considerations

• Type 2 diabetes screening in children: Screen children ≥10 years or at puberty onset if overweight (BMI >85th percentile) plus two risk factors: family history of type 2 diabetes, high-risk race/ethnicity (Native American, African American, Latino, Asian American, Pacific Islander), signs of insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, PCOS), or maternal history of diabetes/GDM 4
• Frequency: Repeat testing every 3 years minimum, or more frequently if BMI is increasing 3
• Diabetes type differentiation: Test pancreatic autoantibodies (GAD-65, IA-2, insulin autoantibodies, ZnT8) if diabetes is diagnosed, as their presence indicates type 1 diabetes; note that ketosis/ketoacidosis does not definitively distinguish type 1 from type 2, as approximately 6% of youth with type 2 diabetes present with DKA 3

Primary Management Strategy

Weight reduction is the most effective and scientifically validated strategy for obesity-associated acanthosis nigricans, with a target of 7-10% decrease in excess weight for obese patients. 1, 2, 5

Treatment of Underlying Conditions

• PCOS management: Implement hormonal therapy to correct hyperandrogenism and restore ovulation while addressing insulin resistance through lifestyle modification and insulin-sensitizing agents 1, 2
• Malignancy-associated AN: Treat the primary cancer; resolution of skin changes typically follows successful oncologic therapy 1
• Medication-induced AN: Discontinue causative drugs when identified 6

Cosmetic Treatment Options (When Underlying Cause Not Amenable to Treatment)

• First-line topical therapy: Topical retinoids, though skin irritation is a limiting factor 5, 7
• Alternative topical agents: Vitamin D analogs (calcipotriol/colecalciferol), keratolytics 5, 6, 8
• Chemical peels: Trichloroacetic acid for localized lesions 5, 6
• Systemic therapy: Oral retinoids for extensive or generalized AN unresponsive to topical therapy 6, 8
• Insulin sensitizers: Metformin may be beneficial in clearing AN associated with insulin resistance 8
• Laser therapy: Long-pulsed alexandrite, fractional 1550-nm erbium fiber, and CO2 lasers have been described 5

Critical Clinical Pitfalls

• Do not rely solely on fasting glucose: OGTT is essential for timely detection of pre-diabetes or diabetes, as fasting glucose alone can miss early glucose intolerance 1
• Do not assume obesity: Although obesity accounts for approximately 80% of AN cases, actively evaluate non-obese individuals to exclude paraneoplastic causes, particularly gastric adenocarcinoma 1, 3
• Recognize cardiovascular risk: Patients with AN and insulin resistance carry markedly increased cardiovascular disease risk due to accompanying dyslipidemia and metabolic syndrome; comprehensive risk stratification and management are warranted 1
• Expect incomplete cosmetic resolution: Although AN is treatable, complete cure and disappearance of lesions are difficult to achieve even with optimal management 5, 6